Sun Pharma Advanced Research Co (SPARC.NS) Stock Price

Sun Pharma Advanced Research Co Price

NSE·CLOSED
197.36INR-0.62 (-0.31 %)
Market closed

Revenue has compounded at 3.9% per year over the past 17 years to 717.66 M INR. Sun Pharma Advanced Research Co's net margin stands at -477.3%, down from -59.7% several years earlier. Analysts set a median price target of 2,080.80 INR, implying 954.3% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 82% above its 52-week low.

Sun Pharma Advanced Research Co stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Sun Pharma Advanced Research Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sun Pharma Advanced Research Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sun Pharma Advanced Research Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Sun Pharma Advanced Research Co Stock Price History
DateSun Pharma Advanced Research Co Price
8/17/2026197.36 INR
8/14/2026197.98 INR
8/13/2026202.07 INR
8/12/2026202.21 INR
8/11/2026205.26 INR
8/10/2026207.38 INR
8/7/2026213.21 INR
8/6/2026216.98 INR
8/5/2026218.35 INR
8/4/2026207.27 INR
7/31/2026206.21 INR
7/30/2026209.46 INR
7/29/2026213.17 INR
7/28/2026212.13 INR
7/24/2026216.23 INR
7/23/2026214.48 INR
7/22/2026213.96 INR
7/21/2026224.52 INR
7/20/2026227.51 INR
7/17/2026235.20 INR
7/16/2026250.45 INR
7/15/2026251.04 INR
7/14/2026247.83 INR
7/13/2026259.42 INR
7/10/2026264.60 INR
7/9/2026277.57 INR
7/8/2026269.98 INR
7/7/2026263.86 INR
7/6/2026261.71 INR
7/3/2026238.85 INR
7/2/2026239.32 INR
7/1/2026237.50 INR
6/30/2026234.75 INR
6/29/2026231.19 INR
6/25/2026224.92 INR
6/24/2026226.86 INR
6/23/2026234.92 INR
6/22/2026238.03 INR
6/19/2026238.09 INR
6/18/2026242.47 INR
6/17/2026239.61 INR
6/16/2026238.41 INR
6/15/2026225.71 INR
6/12/2026208.93 INR
6/11/2026204.11 INR
6/10/2026205.92 INR
6/9/2026209.19 INR
6/8/2026203.60 INR
6/5/2026212.82 INR
6/4/2026212.97 INR
6/3/2026208.50 INR
6/2/2026204.24 INR
6/1/2026196.37 INR
5/29/2026212.11 INR
5/28/2026221.35 INR
5/27/2026221.35 INR
5/26/2026235.57 INR
5/25/2026232.99 INR
5/22/2026209.77 INR
5/21/2026180.33 INR
5/20/2026183.68 INR
5/19/2026179.77 INR
5/18/2026162.23 INR
5/15/2026163.65 INR
5/14/2026170.08 INR
5/13/2026168.68 INR
5/12/2026166.43 INR
5/11/2026168.45 INR
5/8/2026173.09 INR
5/7/2026166.85 INR
5/6/2026157.08 INR
5/5/2026140.00 INR
5/4/2026139.70 INR
5/1/2026143.04 INR
4/30/2026143.04 INR
4/29/2026148.56 INR
4/28/2026146.85 INR
4/27/2026146.72 INR
4/24/2026139.28 INR
4/23/2026142.88 INR
4/22/2026143.54 INR
4/21/2026144.05 INR
4/20/2026144.50 INR
4/17/2026148.01 INR
4/16/2026152.50 INR
4/15/2026150.78 INR
4/13/2026142.39 INR
4/10/2026148.34 INR
4/9/2026146.17 INR
4/8/2026136.16 INR
4/7/2026126.38 INR
4/6/2026122.62 INR
4/2/2026124.06 INR
4/1/2026120.34 INR
3/30/2026114.89 INR
3/27/2026120.89 INR
3/25/2026131.45 INR
3/24/2026111.89 INR
3/23/2026108.71 INR
3/20/2026115.42 INR
3/19/2026115.20 INR
3/18/2026120.25 INR
3/17/2026114.80 INR
3/16/2026114.16 INR
3/13/2026116.83 INR
3/12/2026122.39 INR
3/11/2026125.55 INR
3/10/2026124.37 INR
3/9/2026121.11 INR
3/6/2026123.96 INR
3/5/2026124.08 INR
3/4/2026123.47 INR
3/2/2026125.92 INR
2/27/2026127.08 INR
2/26/2026128.43 INR
2/25/2026130.92 INR
2/24/2026127.50 INR
2/23/2026128.06 INR
2/20/2026129.21 INR
2/19/2026130.88 INR
2/18/2026132.21 INR
2/17/2026134.32 INR
2/16/2026133.69 INR
2/13/2026132.10 INR
2/12/2026135.20 INR
2/11/2026136.96 INR
2/10/2026140.55 INR
2/9/2026138.01 INR
2/6/2026139.16 INR
2/5/2026140.25 INR
2/4/2026141.31 INR
2/3/2026139.61 INR
2/2/2026133.50 INR
1/30/2026126.08 INR
1/29/2026124.98 INR
1/28/2026124.99 INR
1/27/2026123.05 INR
1/23/2026124.94 INR
1/22/2026129.55 INR
1/21/2026128.80 INR
1/20/2026127.99 INR
1/19/2026130.29 INR
1/16/2026133.52 INR
1/15/2026135.44 INR
1/14/2026135.44 INR
1/13/2026135.85 INR
1/12/2026135.26 INR
1/9/2026132.38 INR
1/8/2026135.14 INR
1/7/2026137.89 INR
1/6/2026135.91 INR
1/5/2026135.34 INR
1/2/2026135.72 INR
1/1/2026135.03 INR
12/31/2025134.45 INR
12/30/2025134.45 INR
12/29/2025133.62 INR
12/26/2025134.03 INR
12/24/2025135.61 INR
12/23/2025134.01 INR
12/22/2025139.77 INR
12/19/2025143.82 INR
12/18/2025131.79 INR
12/17/2025130.78 INR
12/16/2025132.85 INR
12/15/2025136.42 INR
12/12/2025136.84 INR
12/11/2025137.30 INR
12/10/2025137.73 INR
12/9/2025142.19 INR
12/8/2025139.95 INR
12/5/2025152.94 INR
12/4/2025152.10 INR
12/3/2025151.55 INR
12/2/2025161.02 INR
12/1/2025134.19 INR
11/28/2025134.51 INR
11/27/2025135.65 INR
11/26/2025133.74 INR
11/25/2025132.83 INR
11/24/2025133.51 INR
11/21/2025136.01 INR
11/20/2025138.06 INR
11/19/2025130.72 INR
11/18/2025130.14 INR
11/17/2025131.42 INR
11/14/2025132.07 INR
11/13/2025131.17 INR
11/12/2025132.99 INR
11/11/2025131.09 INR
11/10/2025131.37 INR
11/7/2025133.35 INR
11/6/2025134.58 INR
11/4/2025136.59 INR
11/3/2025140.14 INR
10/31/2025135.19 INR
10/30/2025136.95 INR
10/29/2025137.72 INR
10/28/2025142.23 INR
10/27/2025133.26 INR
10/24/2025131.37 INR
10/23/2025131.99 INR
10/21/2025131.80 INR
10/20/2025130.01 INR
10/17/2025129.40 INR
10/16/2025131.83 INR
10/15/2025131.28 INR
10/14/2025130.46 INR
10/13/2025134.21 INR
10/10/2025134.01 INR
10/9/2025128.03 INR
10/8/2025128.05 INR
10/7/2025130.44 INR
10/6/2025131.91 INR
10/3/2025132.11 INR
10/1/2025132.15 INR
9/30/2025129.52 INR
9/29/2025128.78 INR
9/26/2025131.76 INR
9/25/2025135.73 INR
9/24/2025137.21 INR
9/23/2025139.39 INR
9/22/2025141.01 INR
9/19/2025143.28 INR
9/18/2025143.87 INR
9/17/2025144.30 INR
9/16/2025143.82 INR
9/15/2025143.67 INR
9/12/2025143.10 INR
9/11/2025144.54 INR
9/10/2025143.94 INR
9/9/2025141.58 INR
9/8/2025141.09 INR
9/5/2025144.96 INR
9/4/2025144.32 INR
9/3/2025146.82 INR
9/2/2025143.52 INR
9/1/2025141.85 INR
8/29/2025140.09 INR
8/28/2025140.27 INR
8/26/2025142.59 INR
8/25/2025144.72 INR
8/22/2025146.08 INR
8/21/2025145.05 INR
8/20/2025146.86 INR
Access this data via the Eulerpool API
Get Free API Key

Sun Pharma Advanced Research Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
2.53 B INR
-1.46 B INR
-1.51 B INR
Jan 1, 2022
1.37 B INR
-1.96 B INR
-2.03 B INR
Jan 1, 2023
2.39 B INR
-2.24 B INR
-2.23 B INR
Jan 1, 2024
755.45 M INR
-4.12 B INR
-3.87 B INR
Jan 1, 2025
717.66 M INR
-3.34 B INR
-3.43 B INR
Jan 1, 2026 (e)
605.16 B INR
-369.73 B INR
17.98 B INR
Jan 1, 2027 (e)
665.26 B INR
160.95 B INR
20.74 B INR
Jan 1, 2028 (e)
740.36 B INR
0.00 INR
0.00 INR

Sun Pharma Advanced Research Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 19, 2026, 4:20 PM
 
REVENUEB INR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB INR
EBITB INR
EBIT MARGIN%
NET INCOMEB INR
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
0.871.671.561.611.810.781.830.772.531.372.390.760.72605.16665.26740.36
201.7391.51-6.773.5312.28-56.80133.76-57.99229.30-45.7573.98-68.37-5.0384,301.399.9311.29
80.5082.1687.5483.3181.3854.2288.1325.7885.4977.6223.00-87.81-62.06-62.06-62.06-62.06
0.701.371.361.341.470.421.610.202.161.070.55-0.66-0.45-375.59-412.89-459.50
-0.200.30-0.42-0.70-1.31-2.51-1.52-3.15-1.46-1.96-2.24-4.12-3.34-369.73160.95–
-22.8217.90-27.10-43.67-72.21-320.59-83.21-410.03-57.61-142.86-93.67-545.03-465.83-61.1024.19–
-0.220.30-0.40-0.70-1.19-1.97-1.45-3.12-1.51-2.03-2.23-3.87-3.4317.9820.74–
-68.98-235.27-230.3676.9670.2465.55-26.19114.86-51.6334.619.3974.02-11.54-624.9115.36–
219.40238.30236.70236.70246.20248.10255.60262.00262.00263.10284.70324.52324.52324.52324.52324.52
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Sun Pharma Advanced Research Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sun Pharma Advanced Research Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sun Pharma Advanced Research Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Sun Pharma Advanced Research Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sun Pharma Advanced Research Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Sun Pharma Advanced Research Co stock margins

The Sun Pharma Advanced Research Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sun Pharma Advanced Research Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sun Pharma Advanced Research Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
85.49 %
-57.60 %
-59.75 %
Jan 1, 2022
77.63 %
-142.86 %
-148.20 %
Jan 1, 2023
23.03 %
-93.66 %
-93.22 %
Jan 1, 2024
-87.87 %
-544.71 %
-512.56 %
Jan 1, 2025
-62.04 %
-465.49 %
-477.26 %
Jan 1, 2026 (e)
-62.04 %
-61.10 %
2.97 %
Jan 1, 2027 (e)
-62.04 %
24.19 %
3.12 %
Jan 1, 2028 (e)
-62.04 %
0.00 %
0.00 %

Sun Pharma Advanced Research Co Stock Revenue, EBIT, Earnings per Share

The Sun Pharma Advanced Research Co earnings per share therefore indicates how much revenue Sun Pharma Advanced Research Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
9.65 INR
-5.56 INR
-5.77 INR
Jan 1, 2022
5.22 INR
-7.45 INR
-7.73 INR
Jan 1, 2023
8.39 INR
-7.86 INR
-7.82 INR
Jan 1, 2024
2.33 INR
-12.68 INR
-11.93 INR
Jan 1, 2025
2.21 INR
-10.29 INR
-10.55 INR
Jan 1, 2026 (e)
1,864.77 INR
-1,139.32 INR
55.40 INR
Jan 1, 2027 (e)
2,049.96 INR
495.97 INR
63.91 INR
Jan 1, 2028 (e)
2,281.40 INR
0.00 INR
0.00 INR

Sun Pharma Advanced Research Co business model & stock analysis

Sun Pharma Advanced Research Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Sun Pharma Advanced Research Co historical P/E ratio, EBIT multiple, and P/S ratio

Sun Pharma Advanced Research Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Sun Pharma Advanced Research Co shares outstanding

The number of shares of Sun Pharma Advanced Research Co was 324.52 M in 2025. This indicates how many shares Sun Pharma Advanced Research Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
262.00 M Stocks
Jan 1, 2022
263.10 M Stocks
Jan 1, 2023
284.70 M Stocks
Jan 1, 2024
324.52 M Stocks
Jan 1, 2025
324.52 M Stocks
Jan 1, 2026 (e)
324.52 M Stocks
Jan 1, 2027 (e)
324.52 M Stocks
Jan 1, 2028 (e)
324.52 M Stocks

Current Sun Pharma Advanced Research Co forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
2,080.80
Last Price
194.97
Currency
INR
12M Return Potential
967.24 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Sun Pharma Advanced Research Co stock

44/100
36
Environment
40
Social
56
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees34
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sun Pharma Advanced Research Co shareholder structure

% Name
0.96964%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.74365%
ICICI Prudential Asset Management Co. Ltd.
ICICI Prudential Asset Management Co. Ltd.
0.58790%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.14391%
State Street Investment Management (US)
State Street Investment Management (US)
0.09464%
Motilal Oswal Asset Management Company Ltd.
Motilal Oswal Asset Management Company Ltd.
0.00520%
Vanguard Global Advisers LLC
Vanguard Global Advisers LLC

Sun Pharma Advanced Research Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
27.1%
Float Shares
-
Shares Outstanding
-

Sun Pharma Advanced Research Co Executives and Management Board

12 members · avg. age 62 · 33 % women

AR

Mr. Anilkumar Raghavan (57)

Chief Executive Officer

56.69 M INR

Management

KD

Ms. Kajal Damania

Compliance Officer, Company Secretary

2.04 M INR
AR

Mr. Anup Rathi

Chief Financial Officer

–
JI

Mr. Jaydeep Issrani

Investor Relations

–

Board of Directors

SD

Smt. Bhavna Doshi

Non-Executive Independent Director

690,000.00 INR
FE

Dr. Ferzaan Engineer (62)

Non-Executive Independent Director

600,000.00 INR
RS

Dr. Robert Spiegel

Non-Executive Independent Director

600,000.00 INR
VS

Ms. Vidhi Shanghvi (37)

Non-Executive Director

480,000.00 INR
DS

Mr. Dilip Shanghvi (69)

Non-Executive Chairman of the Board · since 2006

390,000.00 INR
TR

Dr. Thennati Rajamannar (64)

Non-Executive Director · since 2007

300,000.00 INR

Frequently asked questions about Sun Pharma Advanced Research Co

Analysts currently set an average price target of 2,080.80 INR for the Sun Pharma Advanced Research Co stock (median: 2,080.80 INR), implying +967.2 % versus the latest price. The consensus is based on 9 analyst ratings.

Sun Pharma Advanced Research Co Analyst Price Targets 2026

10 analysts currently rate the Sun Pharma Advanced Research Co stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Sun Pharma Advanced Research Co to generate revenue of 605.16 B INR and earnings per share of 55.40 INR.

Sun Pharma Advanced Research Co Analyst Price Targets 2026

Converted at the current exchange rate, the Sun Pharma Advanced Research Co share trades at 1.78 EUR (197.36 INR).

No history available for Sun Pharma Advanced Research Co.

The expected revenue of Sun Pharma Advanced Research Co is 605.16 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sun Pharma Advanced Research Co is 17.98 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sun Pharma Advanced Research Co is currently 3.56. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sun Pharma Advanced Research Co stock.

The price-to-sales ratio (P/S) of Sun Pharma Advanced Research Co is currently 0.11. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sun Pharma Advanced Research Co stock.

The Eulerpool Quality Score for Sun Pharma Advanced Research Co is 2/10.

The ISIN of Sun Pharma Advanced Research Co is INE232I01014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Sun Pharma Advanced Research Co is SPARC.NS. The ticker symbol is used to trade Sun Pharma Advanced Research Co shares on the stock exchange.

Sun Pharma Advanced Research Co paid dividends every year for the past 0 years.

Sun Pharma Advanced Research Co is assigned to the 'Health' sector.

The dividends of Sun Pharma Advanced Research Co are distributed in INR.

All fundamentals and in-depth analysis of Sun Pharma Advanced Research Co

Our stock analysis for Sun Pharma Advanced Research Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sun Pharma Advanced Research Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Revenue→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Net Income→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co P/E→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co P/S→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co EBIT→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Dividend→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Directors Dealings→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Stocks→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Market capitalization→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Debt→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Liabilities→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Equity→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co AAQS→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Employees→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co ROE→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co ROA→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co ROCE→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co News→
Sun Pharma Advanced Research Co Stock
Sun Pharma Advanced Research Co Analyst Price Targets→

Health Stocks

Sun Pharmaceutical IndustriesSummit TherapeuticsSunder Biomedical Tech CoSummerset Group HoldingsSunflower Pharmaceutical Group CoSumitomo Pharma CoSunho BiologicsSuheung CoSunmax Biotechnology CoSugenTechSunny PharmtechSugarBud Craft GrowersAll Stocks A–Z →